Bioequivalence Study of Lansoprazole DR Capsules 30 mg in Fasting Conditions

Open Label, Randomized, Two-treatment, Three-period, Three-sequence, Partial Replicate Oral Bioequivalence Study of Lansoprazole 30 mg DR Capsules of Dr.Reddy's Laboratories Limited, India Comparing With That of PREVACID® (Containing Lansoprazole) 30 mg DR Capsules of TAP Pharmaceuticals Inc. USA, in Healthy, Adult, Human Subjects Under Fasting Conditions.

The objective of this study was to compare the relative bioavailability of Lansoprazole DR Capsules 30 mg with Prevacid® Capsules 30 mg under fasting conditions in healthy adult human subjects.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: Lansoprazole

Detailed Description

open label, randomized, two-treatment, three-period, three-sequence, partial replicate oral bioequivalence study of Lansoprazole 30 mg DR Capsules of Dr.Reddy's Laboratories Limited, India comparing with that of PREVACID® (containing Lansoprazole) 30 mg DR Capsules of TAP Pharmaceuticals Inc. USA, in healthy, adult, human subjects under fasting conditions. 48 healthy, adult, human subjects were enrolled in the study and 42 subjects were completed the study.

• Study Type: Interventional
• Enrollment (Actual): 48
• Phase: Phase 1

Contacts and Locations

Study Locations

• India
  • Hyderabad
    • Balanagar, Hyderabad, India, 500 037
      • Bioserve Clinical Research (P) Ltd

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

i. Provided written informed consent.

ii. Subject who were healthy, adult, human beings within 18 and 45 years of age (both inclusive) weighing at least 50 kg.

iii. Subject having a body mass index between 18.0 and 29.9 (both inclusive), calculated as weight in Kg/height in m2.

iv. Subject having a normal health as determined by medical history, physical examination and laboratory investigation performed within 28 days prior to the commencement of the study. (Laboratory values must be within normal limits or considered by the physician /investigator to be of no clinical significance).

v. Female Subjects of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.

• postmenopausal for at least 1 year.
• surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject)

Exclusion Criteria:

i. Subject who were incapable of understanding the informed consent.

ii. Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg.

iii. Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg.

iv. Oral temperature is below 95.0°F or above 98.6°F.

v. Pulse rate below 50/min or above 100/min.

vi. History of hypersensitivity or idiosyncratic reaction to investigational drug product or any other related drugs.

vii. Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function.

viii. Consumption of grapefruit for the past ten days prior to the check-in, in each period.

ix. Regular smoker who has a habit of smoking more than nine cigarettes per day and has difficulty in abstaining from smoking during sample collection period.

x. Habit of alcoholism and difficulty in abstaining from alcohol during the sample collection period.

xi. Difficulty in abstaining from xanthene containing food or beverages (like tea, coffee, chocolates and cola drinks) during the sample collection period.

xii. Intake of over the counter (OTC) or prescribed medications and enzyme modifying medication or systemic medication for the last 30 days before dosing.

xiii. Clinically significant abnormalities and / or with significant diseases.

xiv. Confirmed positive in alcohol screening.

xv. Confirmed positive in selected drug of abuse.

xvi. Subjects who had participated in any other clinical investigation using experimental drug/donated blood in past 90 days before the date of start of study

xvii. Confirmed positive in urine pregnancy test.

xviii. Female detected to be pregnant, breast feeding or who is likely to become pregnant during the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Lansoprazole DR Capsules 30 mg; Lansoprazole DR Capsules 30 mg of Dr.Reddy's Laboratories Limited	Drug: Lansoprazole; Lansoprazole DR Capsules 30 mg; Other Names: Prevacid
Active Comparator: Prevacid 30 mg Capsules; Prevacid 30 mg Capsules of TAP Pharmaceuticals Inc. USA	Drug: Lansoprazole; Lansoprazole DR Capsules 30 mg; Other Names: Prevacid

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Bioequivalence based on Cmax and AUC parameters	4 months

Collaborators and Investigators

• Sponsor: Dr. Reddy's Laboratories Limited
• Investigators: Principal Investigator: Dr.M.Venkat Jayanth, MBBS, Bioserve Clinical Research (P) Ltd

Study record dates

Study Major Dates

• Study Start: December 1, 2008
• Primary Completion (Actual): December 1, 2008
• Study Completion (Actual): December 1, 2008

Study Registration Dates

• First Submitted: January 3, 2011
• First Submitted That Met QC Criteria: January 4, 2011
• First Posted (Estimate): January 5, 2011

Study Record Updates

• Last Update Posted (Estimate): January 5, 2011
• Last Update Submitted That Met QC Criteria: January 4, 2011
• Last Verified: February 1, 2009

More Information

Terms related to this study

• Keywords: Bioequivalence; two way crossover
• Additional Relevant MeSH Terms: Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Gastrointestinal Agents; Anti-Ulcer Agents; Proton Pump Inhibitors; Dexlansoprazole; Lansoprazole
• Other Study ID Numbers: P-699/08